We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Activation in Tuberculosis Counters Host Immune Response

By Biotechdaily staff writers
Posted on 05 Apr 2004
Researchers have adapted high-speed gene chip microarray technology to study the pattern of gene activation in Mycobacterium tuberculosis cells growing in normal mice, immune-deficient mice, and in culture.

Investigators at the University of Texas Southwestern Medical Center (Dallas, USA) spent more than two years developing a protocol that allowed high-throughput analysis of genes that were expressed in a pathogent extracted from an infected animal, rather than simply grown in culture. More...


Using this tool they found that M tuberculosis cells removed from mice 21 days after infection showed activity in a set of 67 genes that did not function in cells grown in immune-deficient mice or in culture. The activity of these genes was thought to be required for avoidance of the host's immune response. The finding that bacteria from immune deficient mice displayed the same lack of gene activity as those from culture calls into question the use of immune-deficient mice for drug development studies. These results were published in the March 18, 2004, online issue of the Proceedings of the [U.S.] National Academy of Sciences.

"This is an example of how the high-throughput system is a new avenue to study a variety of pathogens and how they affect living hosts,” said senior author Dr. Stephen Albert Johnston, director of the Center for Biological Inventions at the University of Texas Southwestern Medical Center. "We see it as a tool for vaccine and drug development against disease and the threat of biological weapons. By identifying the genes that cause disease progression in vivo, we can begin to piece together the knowledge that will allow us to discover better targets for drug therapies.”




Related Links:
UT Southwestern Medical Center

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Age-Based Genetic Testing May Miss Most Inherited Cancer Risk Variants

Inherited cancer risk can influence diagnosis, treatment planning, and family screening, yet current testing practices often depend on a patient’s age at diagnosis. Many patients undergo germline genetic... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.